Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for […]
Nancy Bush Huber brings over 25 years of executive management roles, primarily as CFO of several publicly traded and private companies- Most recent position was as CFO of consumer packaged goods company for 13 years- […]
NEW YORK, Nov. 18, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
